If you have been following ResMed, you know the stock has steadily outperformed the market over the past year, gaining 31 percent and rising 19 percent in the past three months alone. That lift reflects both the enthusiasm for the company's leadership in sleep and respiratory care and a broader re-rating in health technology stocks. Beyond boardroom headlines, ResMed has also reported consistent financial results, with revenue and net income both showing healthy annual growth.